08.24.07
Bengt Danielsson, M.D., Ph.D., has been appointed vice president, PharmaNet Consulting. He joins the company from the Swedish Medical Product Agency where he served as scientific director/professor in pharmacology and toxicology for the past three years. During that time he also served as a member and the EU Pharmacology and Toxicology representative of the EMEA/CHMP Innovative Medicine Task Force group and a member and Swedish representative of the CHMP/EU Safety and CHMP/EU Cell-based Products working parties. Dr. Danielsson previously worked for Astra AB and AstraZeneca where he served as global director, clinical interface support and global science leader, reproductive toxicology.
"We are extremely pleased to have someone of Dr. Danielsson's stature join PharmaNet Development Group," commented Dr. James Burns, senior vice president, PharmaNet Consulting. "He adds to an already impressive team of experts in our drug development consulting practice, which includes a number of senior former-FDA officials, and will bring significant technical and regulatory experience to assist our clients who are developing products in Europe."
"We are extremely pleased to have someone of Dr. Danielsson's stature join PharmaNet Development Group," commented Dr. James Burns, senior vice president, PharmaNet Consulting. "He adds to an already impressive team of experts in our drug development consulting practice, which includes a number of senior former-FDA officials, and will bring significant technical and regulatory experience to assist our clients who are developing products in Europe."